HCM
ALNY icon

Hollencrest Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Hollencrest Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$301 Hold
1
– – ﹤0.01% 1148
2026
Q1 		$331 Hold
1
– – ﹤0.01% 1136
2025
Q4 		$398 Buy
+1
New +$443 ﹤0.01% 1105
2025
Q1 		– Sell
-8
Closed -$1.88K – 1123
2024
Q4 		$1.88K Sell
8
-97
-92% -$25.5K ﹤0.01% 1023
2024
Q3 		$28.9K Buy
+105
New +$27.3K ﹤0.01% 604

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hollencrest Capital Management's ALNY Position: Q2 2026 in Review

Hollencrest Capital Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 1 share worth $301. The position accounts for ﹤0.01% of the portfolio, ranked #1148.

Hollencrest Capital Management first reported a position in ALNY in Q3 2024 and has held it in 5 quarters since. The position peaked at $28.9K in Q3 2024. 787 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Hollencrest Capital Management held 1 share of Alnylam Pharmaceuticals worth $301 as of Q2 2026.
  • Hollencrest Capital Management left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Hollencrest Capital Management's portfolio in Q2 2026, its #1148 holding.
  • Hollencrest Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 5 quarters since.
  • Hollencrest Capital Management's Alnylam Pharmaceuticals position peaked at $28.9K in Q3 2024.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Hollencrest Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.